ID   USPC-ARK-20
AC   CVCL_IV91
SY   USPC-ARK20; USC ARK-20; ARK-20; ARK20
DR   cancercelllines; CVCL_IV91
DR   Wikidata; Q54991965
RX   PubMed=23891627;
RX   PubMed=25268372;
RX   PubMed=26325104;
RX   PubMed=26625219;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=23891627; PubMed=26325104).
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
DI   NCIt; C27838; Endometrial serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 11
//
RX   PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020;
RA   English D.P., Bellone S., Cocco E., Bortolomai I., Pecorelli S.,
RA   Lopez S., Silasi D.-A., Schwartz P.E., Rutherford T.J., Santin A.D.;
RT   "Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications
RT   determine the sensitivity of uterine serous carcinoma cell lines to
RT   GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase
RT   (TORC1/2).";
RL   Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013).
//
RX   PubMed=25268372; DOI=10.1038/bjc.2014.519; PMCID=PMC4453741;
RA   Schwab C.L., Bellone S., English D.P., Roque D.M., Lopez S., Cocco E.,
RA   Nicoletti R., Bortolomai I., Bonazzoli E., Ratner E., Silasi D.-A.,
RA   Azodi M., Schwartz P.E., Rutherford T.J., Santin A.D.;
RT   "Afatinib demonstrates remarkable activity against HER2-amplified
RT   uterine serous endometrial cancer in vitro and in vivo.";
RL   Br. J. Cancer 111:1750-1756(2014).
//
RX   PubMed=26325104; DOI=10.1038/bjc.2015.306; PMCID=PMC4651122;
RA   Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L.,
RA   English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E.,
RA   Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.;
RT   "PIK3CA oncogenic mutations represent a major mechanism of resistance
RT   to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.";
RL   Br. J. Cancer 113:1020-1026(2015).
//
RX   PubMed=26625219; DOI=10.1038/bjc.2015.388; PMCID=PMC4705897;
RA   Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L.,
RA   English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E.,
RA   Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.;
RT   "Erratum to: PIK3CA oncogenic mutations represent a major mechanism of
RT   resistance to trastuzumab in HER2/neu overexpressing uterine serous
RT   carcinomas.";
RL   Br. J. Cancer 113:1641-1641(2015).
//